Synlogic Inc (SYBX) - Total Liabilities
Based on the latest financial reports, Synlogic Inc (SYBX) has total liabilities worth $6.23 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Synlogic Inc generate cash to assess how effectively this company generates cash.
Synlogic Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Synlogic Inc's total liabilities have evolved over time, based on quarterly financial data. Check Synlogic Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Synlogic Inc Competitors by Total Liabilities
The table below lists competitors of Synlogic Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tri-Mode System M Bhd
KLSE:0199
|
Malaysia | RM78.39 Million |
|
Sentra Food Indonesia Tbk PT
JK:FOOD
|
Indonesia | Rp65.76 Billion |
|
Evolva Holding SA
SW:EVE
|
Switzerland | CHF849.50K |
|
Vape Holdings Inc
NASDAQ:VAPE
|
USA | $1.23 Million |
|
Lendway Inc.
NASDAQ:LDWY
|
USA | $96.67 Million |
|
Atlas Cycles (Haryana) Limited
NSE:ATLASCYCLE
|
India | Rs966.27 Million |
|
Sersol Bhd
KLSE:0055
|
Malaysia | RM6.07 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Synlogic Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SYBX company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Synlogic Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Synlogic Inc (2013–2024)
The table below shows the annual total liabilities of Synlogic Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.08 Million | -78.49% |
| 2023-12-31 | $32.90 Million | +16.42% |
| 2022-12-31 | $28.25 Million | +2.86% |
| 2021-12-31 | $27.47 Million | -4.30% |
| 2020-12-31 | $28.70 Million | -9.36% |
| 2019-12-31 | $31.67 Million | +94.98% |
| 2018-12-31 | $16.24 Million | +10.78% |
| 2017-12-31 | $14.66 Million | +284.40% |
| 2016-12-31 | $3.81 Million | -35.37% |
| 2015-12-31 | $5.90 Million | -89.79% |
| 2014-12-31 | $57.78 Million | +7.80% |
| 2013-12-31 | $53.60 Million | -- |
About Synlogic Inc
Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-system… Read more